Akebia Therapeutics
AKBA
#7494
Rank
โ‚น36.71 B
Marketcap
โ‚น138.35
Share price
-3.14%
Change (1 day)
-19.12%
Change (1 year)

Revenue for Akebia Therapeutics (AKBA)

Revenue in 2025 (TTM): โ‚น19.46 Billion

According to Akebia Therapeutics's latest financial reports the company's current revenue (TTM ) is โ‚น20.21 Billion. In 2024 the company made a revenue of โ‚น13.74 Billion a decrease over the revenue in the year 2023 that were of โ‚น16.20 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Akebia Therapeutics from 2013 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚น19.46 B41.65%
2024 โ‚น13.74 B-15.19%
2023 โ‚น16.20 B-32.94%
2022 โ‚น24.15 B51.98%
2021 โ‚น15.89 B-26.39%
2020 โ‚น21.59 B-9.6%
2019 โ‚น23.88 B64.46%
2018 โ‚น14.52 B27.82%
2017 โ‚น11.36 B10794.79%
2016 โ‚น0.10 B
2015 N/A
2014 N/A
2013 N/A

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Amgen
AMGN
โ‚น3.231 T 15,882.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
โ‚น5.064 T 24,946.32%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Johnson & Johnson
JNJ
โ‚น8.278 T 40,842.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Nektar Therapeutics
NKTR
โ‚น5.62 B-72.19%๐Ÿ‡บ๐Ÿ‡ธ USA